Syncom Formulations (India) Limited has informed the stock exchanges of a material acquisition under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026. The disclosure was filed on 4th May, 2026 and pertains to the successful purchase of a commercial property from HDFC Bank Ltd.

Acquisition of Commercial Property

Syncom Formulations (India) Limited has completed the acquisition of the entire 7th Floor at Trade Star, Andheri-Kurla Road, Andheri (E), Mumbai-400059. The company's bid for this commercial property was accepted by HDFC Bank Ltd, and the transaction has been concluded with the payment of the full and final consideration.

The key details of the acquisition are summarised below:

Regulatory Disclosure

The acquisition has been classified as material in nature by the company and has been disclosed to BSE Limited and the National Stock Exchange of India Limited in compliance with applicable SEBI regulations. The disclosure was signed by CS Vaishali Agrawal, Company Secretary and Compliance Officer of Syncom Formulations (India) Limited, on 4th May, 2026.

Syncom Formulations (India) Limited is a WHO-GMP and ISO 9001:2015 certified company with its registered office at 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai - 400 093, and its corporate office at 207, Saket Nagar, Indore - 452 018.

Syncom formulations (India) Limited has formally notified stock exchanges that it does not fall under the "Large Corporate" classification as defined by SEBI regulations. The WHO-GMP and ISO 9001-2000 certified pharmaceutical company submitted this confirmation to both BSE and NSE on April 3, 2026.

Regulatory Compliance Confirmation

The company's confirmation specifically references multiple SEBI circulars that define Large Corporate criteria. The primary regulation cited is SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, which was subsequently updated on April 13, 2022. Additionally, the company referenced SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, along with BSE Notice No. 20220427-2 dated April 27, 2022.

Exemption from Annual Disclosure Requirements

By confirming its non-Large Corporate status, Syncom Formulations is exempt from specific regulatory obligations. The company stated that the requirement for submission of Annual Disclosure in Annexure B2 for the financial year ended March 31, 2026, is not applicable. This exemption represents a significant compliance relief for the company, as Large Corporates face additional disclosure and reporting requirements under SEBI regulations.

Company Profile and Operations

Syncom Formulations operates as a WHO-GMP and ISO 9001-2000 certified pharmaceutical company with CIN No. L24239MH1988PLC047759. The company maintains multiple operational locations across India:

• Registered Office: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai-400 093
• Manufacturing Works: 256-257, Sector-I, Pithampur, Dist.-Dhar, M.P. - 454 775
• Corporate Office: 207, Saket Nagar, Near Saket Club, Indore - 452 018

Stock Exchange Communication

The formal communication was signed by Vaishali Agrawal, Company Secretary and Compliance Officer, and submitted to both major Indian stock exchanges. The company requested that this information be disseminated on BSE and NSE websites for investor awareness. This transparent communication approach demonstrates the company's commitment to regulatory compliance and stakeholder information sharing.

The confirmation ensures that investors and market participants are aware of the company's regulatory status and the corresponding compliance obligations that apply to its operations.